StockNews.AI
LUNG
StockNews.AI
195 days

Pulmonx to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

1. Pulmonx will release Q4 2024 financial results on February 19, 2025. 2. The company leads in treatments for chronic obstructive pulmonary disease. 3. Pulmonx's Zephyr Valve is a standard care for severe emphysema globally. 4. A conference call will follow the financial results announcement.

3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results may improve investor sentiment. Past results often affected stock positively.

How important is it?

The earnings call may reveal crucial insights influencing future growth and stock price.

Why Short Term?

Immediate reactions expected around the financial results release. Historically, earnings announcements impact LUNG's price quickly.

Related Companies

COPDLUNGPulmonx
February 05, 2025 16:05 ET  | Source: Pulmonx Corporation REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Wednesday, February 19, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com. ContactBrian JohnstonGilmartin Groupinvestors@pulmonx.com

Related News